Chemotherapy + Immunochemotherapy + Pegfilgrastim

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Non-Hodgkin's Lymphoma

Conditions

Non-Hodgkin's Lymphoma

Trial Timeline

Jun 1, 2006 → Oct 1, 2007

NCT ID

NCT02782845

About Chemotherapy + Immunochemotherapy + Pegfilgrastim

Chemotherapy + Immunochemotherapy + Pegfilgrastim is a approved stage product being developed by Roche for Non-Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02782845. Target conditions include Non-Hodgkin's Lymphoma.

What happened to similar drugs?

5 of 20 similar drugs in Non-Hodgkin's Lymphoma were approved

Approved (5) Terminated (3) Active (12)

🔄Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3

🔄Zoledronic Acid + Vitamin D + Calcium CarbonateNovartisPhase 3

❌Ofatumumab + Rituximab + Ofatumumab + RituximabNovartisPhase 3

🔄rituximab [MabThera/Rituxan] + Standard chemotherapyRochePhase 3

🔄rituximab [Mabthera/Rituxan]RochePhase 3

🔄Chemotherapy (Induction Period) + RituximabRochePhase 3

🔄Rituximab SC + Rituximab IV + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone/PrednisoloneRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02782845	Approved	Completed	Jun 1, 2006	Oct 1, 2007	Non-Hodgkin's Lymphoma

Competing Products

20 competing products in Non-Hodgkin's Lymphoma

See all competitors

Product	Company	Stage	Hype Score
YM155 + Rituximab	Astellas Pharma	Phase 2	35
Tazemetostat	Eisai	Phase 2	35
ONTAK	Eisai	Phase 2	35
Tazemetostat	Eisai	Phase 1	29
ME-401	Kyowa Kirin	Phase 1	29
ME-401	Kyowa Kirin	Phase 2	39
gemcitabine	Eli Lilly	Phase 2	27
gemcitabine + cisplatin + dexamethasone	Eli Lilly	Phase 2	35
LY317615	Eli Lilly	Phase 2	35
LY4584180 + Rituximab	Eli Lilly	Phase 1	36
Bortezomib + Rituximab + Rituximab	Johnson & Johnson	Phase 3	40
HRS-3738	Jiangsu Hengrui Medicine	Phase 1	25
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin	Jiangsu Hengrui Medicine	Phase 2	31
ABT-199 + Ketoconazole	AbbVie	Phase 1	29
ABT-199 + Rifampin	AbbVie	Phase 1	21
[14C]ABT-199 (GDC-0199)	AbbVie	Phase 1	21
ABT-199 + Rituximab + Bendamustine	AbbVie	Phase 1	29
ABBV-291	AbbVie	Phase 1	36
ABT-199	AbbVie	Phase 1	29
Avelumab	Merck	Phase 1	33